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treatment records should minimize the costs of the medical
aid. However, it is also necessary to consider the cost of
the effect achieved and quality price of not only the medi-
cal aid itself but the life quality to be created as a result of
medical intervention. The latter fact is closely connected
with the ethical and moral aspects of the medical aid. It
predetermines the obligatoriness and the content of the in-
formed patient’s consent to medical intervention that must
be a component of the patient’s treatment record. Using
the results of the pharmacoeconomic investigations and
meta-analysis that must cover not only pharmaceutical fa-
cilities but also the other diagnostic may solve the de-
scribed problems and therapeutic services as well. When
developing such a system, it is necessary to consider the
difficulties that may arise as a result of Russia’s current
practice to widely use the low-informative methods of di-
agnostics, low-efficient medicinal preparations, methods
of physical therapy, and the unavailability of medical in-
formation for the patient.
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Pharmacoeconomic studies are increasing in number
along with their use in healthcare decision-making. The
methods and analyses used in these studies are often new
to clinicians; thus, clinicians may often find it difficult to
read, interpret, assess, and use these studies in their own
decision-making when comparing products. 
OBJECTIVE: In late 1997, the American College of Neu-
ropsychopharmacology (ACNP) convened a task force
charged with developing methodological standards that
could be used to evaluate CNS-related (e.g., psychiatric,
neurologic) pharmacoeconomic studies and be used to
rate these studies. 
METHODS: The Task Force was comprised of members
of the ACNP, non-ACNP scientists, and representatives of
the pharmaceutical industry with expertise and interest in
pharmacoeconomics. The Task Force first compiled a draft
set of rating criteria from existing criteria and other guide-
lines for pharmacoeconomic studies. Two separate rounds
of feasibility tests were conducted during which Task
Force members evaluated three pharmacoeconomic studies
using the initial and the revised rating scale. 
RESULTS: To date, a working rating scale using a 6-point
Likert-type responses has been developed which includes
29 aspects of a pharmacoeconomic study over the follow-
ing seven domains: scope of study, study objectives, sam-
ple, methods, definitions, results and discussion, and con-
clusions. The scale is under consideration for use by the
ACNP pending further refinement. 
CONCLUSIONS: A rating scale has been developed by
which to assess pharmacoeconomic studies within a clini-
cal specialty area. Further testing is needed to refine the
scale and assess its psychometric properties.
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Patient-level healthcare costs are frequently estimated us-
ing claims databases or financial records (e.g., hospital
bills and institutional cost reports). However, in some
healthcare settings, particularly staff model HMOs, this
information is absent. 
OBJECTIVE: To develop a methodology for estimating
costs of healthcare services in the absence of financial
data at a staff-model HMO, using the Asthma Outcomes
Registry as a case study. 
METHODS: The Asthma Outcomes Registry compiled
clinical and economic data on individual asthmatic sub-
jects from three US managed care sites. Two sites pro-
vided data on utilization and cost of healthcare services
derived from health insurance claims. The third site, a
staff-model HMO, provided data on service utilization
but not cost. We used claims data from the two sites that
provided it to impute unit costs of services for treatment
of asthma and allergic rhinitis at the third site. Analysis
of covariance models were fitted to the logarithm of cost
per encounter (or per inpatient day) for patients with
such data, and these models were used to assign a cost
(retransformed logarithm) to each healthcare encounter
at the staff-model HMO. To preserve variation, each en-
counter’s cost was drawn randomly from the distribution
(mean and variance) estimated from the other two sites. 
RESULTS: Estimated geometric mean costs (logarithms 
standard error) of outpatient encounters for asthma and
allergic rhinitis were $78.26 ($4.36  0.014) and $66.02
($4.19  0.032), respectively. Corresponding estimates
for emergency visits and inpatient days for asthma were
$208.51 ($5.34  0.059) and $820.57 ($6.71  0.092).
Visits for allergy testing were estimated to cost $25.03
($3.22  0.009). 
CONCLUSION: Diagnosis-specific unit costs of medical
encounters can be imputed in settings where such data
are absent using data from comparable settings.
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OBJECTIVE: The purpose of this study is to develop
cost-effectiveness methodology in the context of a simul-
taneous modeling framework that provides consistent
point and interval estimations. 
METHODS: A system of cost and effectiveness equations
is suggested to model the simultaneity of the underlying
cost and effectiveness variables, directly producing a mar-
ginal-effect measure of the incremental cost-effectiveness
ratio of two competing medical interventions in an evalua-
tive study. Empirical estimation of the simultaneous cost-
effectiveness model was conducted using a feasible non-
linear least squares estimation method. A simulation
analysis of hypothetical data was performed to show the
superior performance of the marginal-effect approach,
relative to the traditional average-effect approach. 
RESULTS: Traditional average-effect approach has two
shortcomings. First, it assumes two strong conditions:
truly random distributions of all the significant non-
intervention variables (both observed and unobserved)
across a study’s intervention and control groups, and the
independence of cost and effectiveness variables. Second,
it does not give a confidence interval, an important mea-
sure to assess the stochastic nature and robustness of
point estimates. In contrast, the simultaneous marginal-
effect approach imposed no restrictions on the random-
ness of the across-group distributions of all the variables.
Furthermore, it takes into account the simultaneity of
cost and effectiveness functions in estimation. The simu-
lation analysis showed that the marginal-effect approach
is significantly more robust, efficient, and unbiased than
the average-effect approach in predicting the population
true parameters assumed. 
CONCLUSION: The simultaneous marginal-effect ap-
proach should be chosen over the conventional average-
effect approach whenever data allows in assessing the
cost-effectiveness of competing interventions in medical
decision-making.
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OBJECTIVE: To understand the evolution and current
state of the field, we conducted a formal audit of published
cost-utility analyses (CUAs). The objectives were to: 1) de-
velop and test an auditing process for judging the transpar-
ency and uniformity of analyses; 2) examine variations in
practices in previously published studies; 3) determine
whether methods used have been consistent with standard
recommendations; and 4) investigate whether analyses
have been improving over time. 
METHODS: A systematic search of the English-language
medical literature identified 228 original CUAs published
from 1976 through 1997. Each article was audited inde-
pendently by two trained readers using a standard data
collection form to determine quality, completeness, and
clarity. Data were collected on: 1) background; 2) framing;
3) cost estimation; 4) effectiveness estimation; 5) QALY
estimation; 6) reporting of results; 7) discussion; 8) cost/
QALY ratios; and 9) readers’ subjective assessment of
overall quality. 
RESULTS: Cost-utility analyses have covered a wide range
of diseases and interventions. Most studies have ade-
quately described the comparator intervention (83%), ap-
propriately conducted incremental analysis (86%), dis-
counted both costs and QALYs (72%), and performed
sensitivity analysis (89%). Only 52% clearly stated the
study perspective; 34% did not disclose the funding
source. Methods for estimating costs, effectiveness, and
QALYs have varied widely. The quality of published anal-
yses has improved somewhat over time. 
CONCLUSION: The results reveal an active and evolving
field, but also underscore the need for more consistency
and transparency. Concerns about the comparability and
credibility of analyses would be allayed with more uniform
methods for performance and reporting. Better peer re-
view and independent, third-party audits of the kind used
here would likely help in this regard.
USE OF PHARMACOECONOMICS: 
COUNTRY-SPECIFIC ISSUES
PUP1
PHARMACOECONOMICS IN RUSSIA: 
FIRST STEPS
Moisseyev S
Moscow Medical Academy, Moscow, Russia
Pharmacoeconomics is one of the most rapidly developing
sciences in Western countries. The principles of economic
analysis are widely accepted and used. In Russia the situa-
tion is almost completely the reverse. The economic im-
pact of new therapies is usually ignored while the use of
drugs is dictated by tradition and price The result is non-
evidence-based and non-economically-based clinical prac-
tice. The list of best selling drugs in Russia today includes
several drugs unheard of in the West. Many drugs which
are in high demand have no proven efficacy. Inadequate
healthcare financing has put procedure on public purchas-
ing authorities and prescribers to supply the cheapest
drugs and generic equivalents sometimes of poor quality.
One of the ways to solve the problem is to implement the
principles of economic evaluation to policy-making and
general practice though the lack of specialists in pharma-
coeconomics is an obvious obstacle. Despite several signs
of improvement there is still a lot to do. During the last
several years a few steps were made to accomplish this
goal. They include the creation of Center of Evidence-
Based Medicine and Russian branch of ISPOR. Today their
main task seems to be dissemination of knowledge through
